|
A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS). |
Rivaroxaban |
15786 |
NCT01776424 |
MACE prevention |
Phase 3 |
|
|
|
|
Since study is still ongoing, data provided will be on basis of datasets provided to authorities for obtaining market approval. |
April 2019 |